Download Files:
Opicapone
SKU
HY-14896-10 mg
Category Reference compound
Tags COMT, Metabolic Enzyme/Protease;Neuronal Signaling, Neurological Disease
$176 – $1,540
Products Details
Product Description
– Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson’s disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM[1].
Web ID
– HY-14896
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C15H10Cl2N4O6
References
– [1]Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165.|[2]Bonifácio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52.
CAS Number
– 923287-50-7
Molecular Weight
– 413.17
Compound Purity
– 99.19
SMILES
– CC1=[N+]([O-])C(Cl)=C(C2=NOC(C3=CC([N+]([O-])=O)=C(O)C(O)=C3)=N2)C(C)=C1Cl
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ mg/mL
Target
– COMT
Pathway
– Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.